---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014849"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:34:04.415602+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio Q2 net loss $16.2M; completes uBriGene asset sale for $6M

## Summary
- Cash and equivalents $16.1M at June 30, down from $76.7M at Dec 31, 2022, reflecting Runway loan repayment.
- Net loss $16.2M ($2.00/share) vs $19.1M ($2.50/share) in Q2 2022.
- Closed amended asset sale to uBriGene for $6M upfront; expects $28M annual cost reduction.
- Lead CAR T MB-106 shows 83% response in WM cohort; 95% ORR in FL cohort.
- First pivotal Phase 2 WM patient expected Q1 2024; additional multicenter data in Q4 2023.

## SEC filing metadata
- accession: 0001558370-23-014849
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837023014849/0001558370-23-014849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837023014849/tmb-20230814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014849
- JSON: https://secwatch.observer/filing/0001558370-23-014849.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014849.txt

## Key facts
- Earnings Releases
  MUSTANG BIO, INC. reported the second quarter ended June 30, 2023 results: net income Net loss attributable to common stockholders was $16.2 million, or $2.00 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss attributable to common stockholders was $16.2 million, or $2.00 per share
  - Result: reported results
  source text: On August 14, 2023, Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680048/000155837023014849/0001558370-23-014849-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.